Skip to Main Content

Paper Details

Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
J Clin Oncol
43
2022
ALT, B-ALL, B-Cell Acute Lymphoblastic Leukemia, B-cell acute lymphoblastic leukemia, CD22, CD22-positive, CD22-positive B-ALL, Children, InO, Inotuzumab Ozogamicin, SOS, children, cytopenias, hematopoietic stem-cell, hyperbilirubinemia, inotuzumab ozogamicin, patient, patients, refractory (R, sinusoidal obstruction syndrome
Author NameAffiliation
Patrick BrownJohns Hopkins Kimmel Cancer Center
Patrick BrownJohns Hopkins Kimmel Cancer Center
Meenakshi DevidasSt Jude Children's Research Hospital
Mignon L LohBenioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
  • 1 - 4

Datasets

Release 1.2